Study to Assess the Safety of AZD1480 in Patients with Myeloproliferative Diseases

Study identifier:D1060C00001

ClinicalTrials.gov identifier:NCT00910728

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients with Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF

Medical condition

Primary Myelofibrosis (PMF)

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD1480

Sex

All

Actual Enrollment

65

Study type

Interventional

Age

25 Years - 99 Years

Date

Study Start Date: 01 May 2009
Primary Completion Date: 01 Mar 2012
Study Completion Date: 01 Aug 2014

Study design

Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Mar 2017 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

University of Texas, New York City Hoffman Center, Institut Gustave Roussy

Inclusion and exclusion criteria